These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21720868)

  • 1. Cost effectiveness of golimumab for the treatment of active psoriatic arthritis.
    Cummins E; Asseburg C; Prasad M; Buchanan J; Punekar YS
    Eur J Health Econ; 2012 Dec; 13(6):801-9. PubMed ID: 21720868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Golimumab for the treatment of psoriatic arthritis.
    Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.
    Yang H; Craig D; Epstein D; Bojke L; Light K; Bruce IN; Sculpher M; Woolacott N
    Pharmacoeconomics; 2012 Apr; 30(4):257-70. PubMed ID: 22283690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.
    Cummins E; Asseburg C; Punekar YS; Shore E; Morris J; Briggs A; Fenwick E
    Value Health; 2011 Jan; 14(1):15-23. PubMed ID: 21211482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis.
    Cawson MR; Mitchell SA; Knight C; Wildey H; Spurden D; Bird A; Orme ME
    BMC Musculoskelet Disord; 2014 Jan; 15():26. PubMed ID: 24444034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.
    Bravo Vergel Y; Hawkins NS; Claxton K; Asseburg C; Palmer S; Woolacott N; Bruce IN; Sculpher MJ
    Rheumatology (Oxford); 2007 Nov; 46(11):1729-35. PubMed ID: 17956918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK.
    Buchanan V; Sullivan W; Graham C; Miles L; Jugl SM; Gunda P; Halliday A; Kirkham B
    Pharmacoeconomics; 2018 Jul; 36(7):867-878. PubMed ID: 29797187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
    Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
    Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
    Kavanaugh A; McInnes I; Mease P; Krueger GG; Gladman D; Gomez-Reino J; Papp K; Zrubek J; Mudivarthy S; Mack M; Visvanathan S; Beutler A
    Arthritis Rheum; 2009 Apr; 60(4):976-86. PubMed ID: 19333944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis.
    Bojke L; Epstein D; Craig D; Rodgers M; Woolacott N; Yang H; Sculpher M
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv39-iv47. PubMed ID: 21859705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.
    Borse RH; Brown C; Muszbek N; Chaudhary MA; Kachroo S
    Rheumatol Ther; 2017 Dec; 4(2):427-443. PubMed ID: 28956301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany.
    Gandjour A; Ostwald DA
    Appl Health Econ Health Policy; 2020 Feb; 18(1):109-125. PubMed ID: 31701482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study.
    Kavanaugh A; McInnes IB; Mease PJ; Krueger GG; Gladman DD; van der Heijde D; Mudivarthy S; Xu W; Mack M; Xu Z; Beutler A
    Ann Rheum Dis; 2013 Nov; 72(11):1777-85. PubMed ID: 23161902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model to Determine the Cost-Effectiveness of Screening Psoriasis Patients for Psoriatic Arthritis.
    Iragorri N; Hazlewood G; Manns B; Bojke L; Spackman E;
    Arthritis Care Res (Hoboken); 2021 Feb; 73(2):266-274. PubMed ID: 31733035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system.
    Yang TS; Chi CC; Wang SH; Lin JC; Lin KM
    Int J Rheum Dis; 2016 Oct; 19(10):1002-1009. PubMed ID: 26404916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG; Halilovic J; Stan-Ugbene O
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.